Daily News

Daily News

Review of clinical trials concludes ashwagandha extract improved performance on cognitive tasks, executive function, attention and reaction time

Clinical Trials Daily

2019 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Research findings on Neurodegenerative Diseases and Conditions - Dementia are discussed in a new report. According to news originating from Singapore, Singapore, by NewsRx correspondents, research stated, “Many developed countries are experiencing a rapidly ‘greying’ population, and cognitive decline is common in the elderly. There is no cure for dementia, and pharmacotherapy options to treat cognitive dysfunction provide limited symptomatic improvements.”

Our news journalists obtained a quote from the research from MOH Holdings Pte. Ltd., “Withania somnifera (Ashwagandha), a popular herb highly valued in Ayurvedic medicine, has often been used to aid memory and cognition. This systematic review thus aimed to evaluate the clinical evidence base and investigate the potential role of W. somnifera in managing cognitive dysfunction. Using the following keywords [withania somnifera OR indian ginseng OR Ashwagandha OR winter cherry] AND [brain OR cognit* OR mental OR dementia OR memory], a comprehensive search of PubMed, EMBASE, Medline, PsycINFO and Clinicaltrials.gov databases found five clinical studies that met the study’s eligibility criteria. Overall, there is some early clinical evidence, in the form of randomized, placebo-controlled, double-blind trials, to support the cognitive benefits of W. somnifera supplementation. However, a rather heterogeneous study population was sampled, including older adults with mild cognitive impairment and adults with schizophrenia, schizoaffective disorder, or bipolar disorder. In most instances, W. somnifera extract improved performance on cognitive tasks, executive function, attention, and reaction time.”

According to the news editors, the research concluded: “It also appears to be well tolerated, with good adherence and minimal side effects.”

For more information on this research see: A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction. Phytotherapy Research, 2019;():. Phytotherapy Research can be contacted at: John Wiley & Sons LTD, the Atrium, Southern Gate, Chichester PO19 8SQ, W Sussex, England. (Wiley-Blackwell - http://www.wiley.com/; Phytotherapy Research - http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1573)

The news correspondents report that additional information may be obtained from Q.X. Ng, MOH Holdings Pte. Ltd., 1 Maritime Square, 099253, Singapore, Singapore. Additional authors for this research include W. Loke, N.X. Foo, W.J. Tan, H.W. Chan, D.Y. Lim and W.S Yeo.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/ptr.6552. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal Phytotherapy Research is: John Wiley & Sons LTD, the Atrium, Southern Gate, Chichester PO19 8SQ, W Sussex, England.

(Our reports deliver fact-based news of research and discoveries from around the world.)